Developments in international guidelines mark pivotal moment for the heart failure community

News & Events

13 September 2022

In the past two years, both the European Society of Cardiology (ESC) and the American Heart Association (AHA) have published new heart failure guidelines, reflecting significant recent findings related to the diagnosis and treatment of the syndrome. Research continues to progress and will shape future recommendations, including offering renewed hope for people living with heart failure with preserved ejection fraction. This is a pivotal moment for the heart failure community, and a chance for anyone passionate about the care of people with heart failure, to draw the attention of decision-makers to the value of guideline-recommended care.

To aid in this endeavour, HFPN has launched a dedicated resource for heart failure advocates: What’s new in international heart failure guidelines? The resource forms part of our wider programme of work, ‘From guidelines to action’, alongside a report and animation published in June 2022. It summarises the key changes in the ESC and AHA guidelines and considers what other developments we may expect in the future.

Importantly, the new resource provides tips on how heart failure advocates might advance the case for access to guideline-recommended care for everyone living with heart failure.

Download the resource


More from News & Events

9 things we learnt from the Heart Failure Policy Summit 2022
9 things we learnt from the Heart Failure Policy Summit 2022...
13 January 2023
Last year's Summit brought together experts from the heart failure and wider health advocacy communities. Here, we reflect on some learning points....
Read article
Innovation in heart failure: how can we ensure early diagnos
Innovation in heart failure: how can we ensure early diagnos...
08 December 2022
Our ‘Innovation in heart failure: early diagnosis in community settings’ report outlines the urgent need to boost timely diagnosis and presents a variety of promising initiativ...
Read article
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca, CSL Vifor, Boehringer Ingelheim and Roche Diagnostics. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership .